NCT02910011View on ClinicalTrials.gov

Topical NanoDox® for Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

May 18, 2017

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Dermatitis, Atopic
Interventions
DRUG

Nanodox 1% (doxycycline monohydrate hydrogel)

Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner

Trial Locations (2)

32608

UF HealthStreet, Gainesville

32653

UF Health Springhill, Gainesville

Sponsors

Collaborators (1)

Alchem Laboratories, Inc
All Listed Sponsors
collaborator

Alchem Laboratories, Inc

INDUSTRY

lead

University of Florida

OTHER

NCT02910011 - Topical NanoDox® for Atopic Dermatitis | Biotech Hunter | Biotech Hunter